BT8009 monotherapy in enfortumab vedotin (EV)-naive patients (pts) with metastatic urothelial carcinoma (mUC): Updated results of Duravelo-1

被引：1

作者：

Reig Torras, O. ^{[1
]}

Crouzet, L. ^{[2
]}

Necchi, A. ^{[3
,4
]}

Baldini, C. ^{[5
]}

Lostes Bardaji, M. J. ^{[6
,7
]}

Doger de Speville, B. ^{[8
]}

Italiano, A. ^{[9
,10
]}

Verlingue, L. ^{[11
]}

Boni, V. ^{[12
]}

Carter, L. ^{[13
,14
]}

Duran, I. ^{[15
]}

Garmezy, B. ^{[16
]}

Galsky, M. D. ^{[17
]}

Falchook, G. S. ^{[18
]}

DeMars, L. ^{[19
]}

Josephs, K. ^{[20
]}

Xu, C. ^{[21
]}

Bader, J. ^{[22
]}

Fontana, E. ^{[23
]}

机构：

[1] Hosp Clin Barcelona, Dept Med Oncol, Barcelona, Spain

[2] Ctr Eugene Marquis, UNICANCER, Rennes, France

[3] Univ Vita Salute San Raffaele, Dept Med Oncol, Milan, Italy

[4] IRCCS Osped San Raffaele, Dept Med Oncol, Milan, Italy

[5] Gustave Roussy Canc Campus, Drug Dev Dept DITEP, Villejuif, France

[6] Vall DHebron Univ Hosp, Oncol Dept, Barcelona, Spain

[7] Vall dHebron Inst Oncol, Oncol Dept, Barcelona, Spain

[8] START Madrid FJD Hosp Univ Fdn Jimenez Diaz, Start Madrid Phase Unit 1, Madrid, Spain

[9] Inst Bergonie, Early Phase Trials Unit, Bordeaux, France

[10] Univ Bordeaux, Bordeaux, France

[11] Ctr Leon Berard, Phase Clin Unit 1, Lyon, France

[12] NEXT Madrid, Univers Hosp Quiron Salud Madrid, Madrid, Spain

[13] Univ Manchester, Med Oncol, Manchester, Lancs, England

[14] Christie NHS Fdn Trust, Manchester, Lancs, England

[15] Hosp Univ Marques de Valdecilla IDIVAL, Dept Despacho 271, Santander, Spain

[16] Sarah Cannon Res Inst, Med Oncol, Nashville, TN USA

[17] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY USA

[18] HealthONE, Sarah Cannon Res Inst, Med Oncol, Denver, CO USA

[19] Bicycle Therapeut, Clin Dev, Cambridge, MA USA

[20] Bicycle Therapeut, Clin Sci, Cambridge, MA USA

[21] Bicycle Therapeut, Biostat, Cambridge, MA USA

[22] Bicycle Therapeut, Quantitat Pharmacol, Cambridge, MA USA

[23] Sarah Cannon Res Inst UK, Drug Dev, London, England

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.08.718

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

652P

引用

页码：S515 / S516

页数：2

共 50 条

[31] Clinical outcomes by sex with atezolizumab (atezo) monotherapy in patients (pts) with locally advanced/metastatic urothelial carcinoma (mUC)
Hoffman-Censits, J.
Rosenberg, J. E.
van Der Heijden, M.
Dreicer, R.
Perez Gracia, J. L.
Petrylak, D. P.
Retz, M. M.
Sabbatini, R.
Naglieri, E.
Caserta, C.
Maruzzo, M.
Iacovelli, R.
Galli, L.
McDermott, R.
Morales Barrera, R.
Bonfill, T.
De Ducla, S.
Ding, B.
Linsenmeier, J.
Sternberg, C. N.
ANNALS OF ONCOLOGY, 2019, 30 : 372 - +
[32] EV-301: Phase Ill study to evaluate enfortumab vedotin (EV) versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial cancer (Ia/mUC).
Petrylak, Daniel Peter
Rosenberg, Jonathan E.
Duran, Ignacio
Loriot, Yohann
Sonpavde, Guru
Wu, Chunzhang
Gartner, Elaina M.
Melhem-Bertrandt, Amal
Powles, Thomas
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
[33] Real-world evidence for enfortumab vedotin (EV) in metastatic urothelial carcinoma (mUC): a multi-centred observational study in a publicly funded Canadian system.
Peng, Jenny
Hueniken, Katrina
Proulx-Rocray, Francis
Alimohamed, Nimira S.
Fallah-rad, Nazanin
Kumar, Vikaash
Al-Ezzi, Esmail M.
Jiang, Di
Blais, Normand
Sridhar, Srikala S.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[34] Primary results of EV-301: A phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial carcinoma.
Powles, Thomas
Rosenberg, Jonathan E.
Sonpavde, Guru
Loriot, Yohann
Duran, Ignacio
Lee, Jae-Lyun
Matsubara, Nobuaki
Vulsteke, Christof
Wu Chunzhang
Campbell, Mary S.
Matsangou, Maria
Petrylak, Daniel Peter
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
[35] Outcomes in patients (pts) with advanced urothelial carcinoma (aUC) treated with enfortumab vedotin (EV) after switch maintenance avelumab (MAv) in the UNITE study.
Nizam, Amanda
Jindal, Tanya
Jiang, Cindy Y.
Alhalabi, Omar
Bakaloudi, Dimitra Rafailia
Talukder, Rafee
Davidsohn, Matthew P.
Nguyen, Charles B.
Oh, Eugene
Taylor, Amy K.
Lemke, Emily
Kilari, Deepak
Hoimes, Christopher J.
Emamekhoo, Hamid
Gupta, Shilpa
Bellmunt, Joaquim
Grivas, Petros
Campbell, Matthew T.
Alva, Ajjai Shivaram
Koshkin, Vadim S.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 537 - 537
[36] Study EV-103: Neoadjuvant treatment with enfortumab vedotin monotherapy in cisplatinin-eligible patients (pts) with muscle invasive bladder cancer (MIBC): Updated results for Cohort H.
Flaig, Thomas W.
Rosenberg, Jonathan E.
Hoimes, Christopher J.
O'Donnell, Peter H.
Mar, Nataliya
Gourdin, Theodore Stewart
Henry, Stephanie
Bilen, Mehmet Asim
George, Saby
Barata, Pedro C.
Srinivas, Sandy
Rao, Santosh Keshay
Assikis, Vasily J.
Burgess, Earle F.
Ramamurthy, Chethan
Haas, Gabriel P.
Lukas, Jason Jerome
Mildiner-Earley, Shirly
Yu, Yao
Petrylak, Daniel P.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[37] EV-301: A phase III trial in progress evaluating enfortumab vedotin versus chemotherapy in patients with locally advanced or metastatic urothelial carcinoma
Petrylak, D. P.
Rosenberg, J. E.
Lee, J.
Yonese, J.
Duran, I.
Loriot, Y.
Sonpavde, G.
Wu, C.
Gartner, E. M.
Melhem-Bertrandt, A.
Powles, T.
ANNALS OF ONCOLOGY, 2019, 30
[38] EV-302: Updated analysis from the phase 3 global study of enfortumab vedotin in combination with pembrolizumab (EV plus P) vs chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC).
Powles, Thomas
van der Heijden, Michiel Simon
Loriot, Yohann
Bedke, Jens
Valderrama, Begona P.
Iyer, Gopa
Kikuchi, Eiji
Hoffman-Censits, Jeannie
Vulsteke, Christof
Drakaki, Alexandra
Rausch, Steffen
Arafat, Waddah
Park, Se Hoon
Swami, Umang
Li, Jian-Ri
Gorla, Seema Rao
Homet Moreno, Blanca
Yu, Xuesong
Lu, Yi-Tsung
Gupta, Shilpa
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)
[39] Enfortumab vedotin (EV) in combination with pembrolizumab (P) versus chemotherapy in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC): Subgroup analyses results from EV-302, a phase 3 global study
Van Der Heijden, Michiel Simon
Powles, Thomas
Gupta, Shilpa
Bedke, Jens
Kikuchi, Eiji
De Wit, Ronald
Galsky, Matt D.
Duran, Ignacio
Necchi, Andrea
Retz, Margitta
Yu, Evan Y.
Hoffman-Censits, Jean H.
Iyer, Gopa
Park, Se Hoon
Su, Wen-Pin
Parmar, Hema
Guan, Xuesong
Gorla, Seema Rao
Homet Moreno, Blanca
Valderrama, Begona Perez
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : LBA530 - LBA530
[40] Quality of life of metastatic urothelial cancer (mUC) patients treated with enfortumab vedotin (EV) following platinum-containing chemotherapy and a checkpoint inhibitor (CPI): Data from EV-201 cohort 1
McGregor, B. A.
O'Donnell, P. H.
Balar, A.
Petrylak, D. P.
Rosenberg, J. E.
Yu, E.
Quinn, D. I.
Shah, S. N.
Pinelli, J.
Hepp, Z.
Galsky, M.
ANNALS OF ONCOLOGY, 2019, 30

← 1 2 3 4 5 →